The Pharma Letter3d
J&J reports strong data for Tecvayli at ASH 2024
Johnson & Johnson announces positive Phase II results for Tecvayli in newly diagnosed multiple myeloma, with all patients ...
J&J : TECVAYLI Shows Promise As Frontline Therapy For Newly Diagnosed Multiple Myeloma
Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...
J&J announces new frontline data featuring TECVAYLI fro 2 studies in NDMM
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...
PharmiWeb3d
TECVAYLI® (teclistamab) demonstrates potential as…
Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®â–¼ (teclistamab) from two investigational studies in patients with newly diagnosed ...
TECVAYLI® (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
(MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a ...